Equities researchers at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00. The company has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
About Genocea Biosciences
Read More
- Five stocks we like better than Genocea Biosciences
- The 3 Best Retail Stocks to Shop for in August
- The Charles Schwab Company Can Hit New Highs
- ESG Stocks, What Investors Should Know
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- What is the Shanghai Stock Exchange Composite Index?
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.